1. Home
  2. NTLA vs CTEV Comparison

NTLA vs CTEV Comparison

Compare NTLA & CTEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • CTEV
  • Stock Information
  • Founded
  • NTLA 2014
  • CTEV 1980
  • Country
  • NTLA United States
  • CTEV United States
  • Employees
  • NTLA N/A
  • CTEV N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • CTEV
  • Sector
  • NTLA Health Care
  • CTEV
  • Exchange
  • NTLA Nasdaq
  • CTEV NYSE
  • Market Cap
  • NTLA 794.5M
  • CTEV 661.2M
  • IPO Year
  • NTLA 2016
  • CTEV N/A
  • Fundamental
  • Price
  • NTLA $10.68
  • CTEV $45.43
  • Analyst Decision
  • NTLA Buy
  • CTEV Buy
  • Analyst Count
  • NTLA 19
  • CTEV 1
  • Target Price
  • NTLA $35.11
  • CTEV $44.00
  • AVG Volume (30 Days)
  • NTLA 4.9M
  • CTEV 164.4K
  • Earning Date
  • NTLA 08-07-2025
  • CTEV 07-31-2025
  • Dividend Yield
  • NTLA N/A
  • CTEV N/A
  • EPS Growth
  • NTLA N/A
  • CTEV N/A
  • EPS
  • NTLA N/A
  • CTEV N/A
  • Revenue
  • NTLA $45,569,000.00
  • CTEV $927,446,000.00
  • Revenue This Year
  • NTLA N/A
  • CTEV $2.40
  • Revenue Next Year
  • NTLA N/A
  • CTEV $3.12
  • P/E Ratio
  • NTLA N/A
  • CTEV N/A
  • Revenue Growth
  • NTLA N/A
  • CTEV N/A
  • 52 Week Low
  • NTLA $5.90
  • CTEV $4.80
  • 52 Week High
  • NTLA $28.18
  • CTEV $48.52
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 69.70
  • CTEV N/A
  • Support Level
  • NTLA $8.98
  • CTEV N/A
  • Resistance Level
  • NTLA $11.08
  • CTEV N/A
  • Average True Range (ATR)
  • NTLA 0.69
  • CTEV 0.00
  • MACD
  • NTLA 0.16
  • CTEV 0.00
  • Stochastic Oscillator
  • NTLA 88.96
  • CTEV 0.00

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About CTEV CLARITEV CORPORATION

Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.

Share on Social Networks: